Patients with co-existing atrial fibrillation (AF) and chronic kidney disease (CKD)
Oral anticoagulation (OAC)
This review highlights the complex pathophysiology linking atrial fibrillation and chronic kidney disease, and the ongoing uncertainty regarding optimal oral anticoagulation strategies in this population.
Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related conditions with shared risk factors. The growing prevalence of both AF and CKD indicates that more patients will suffer from concurrent conditions. There are various complex interlinking mechanisms with important implications for the management of these patients. Furthermore, there is uncertainty regarding the use of oral anticoagulation (OAC) in AF and CKD that is reflected by a lack of consensus between international guidelines. Therefore, the importance of understanding the implications of co-existing AF and CKD should not be underestimated. In this review, we discuss the pathophysiology and association between AF and CKD, including the underlying mechanisms, risk of thrombo-embolic and bleeding complications, influence on stroke management, and evidence surrounding the use of OAC for stroke prevention.
Building similarity graph...
Analyzing shared references across papers
Loading...
Wern Yew Ding
Dhiraj Gupta
Christopher F. Wong
Cardiovascular Research
University of Liverpool
Aalborg University
Royal Liverpool University Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Ding et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69f14cccb5f6a2886736ecb6 — DOI: https://doi.org/10.1093/cvr/cvaa258